1 Biotech Fast-Tracked to Failure

In what seemed like a promising biotech success story, investors are reminded again about the dangers of putting their money in development-stage drugmakers after GTx collapsed 65% following a failed late-stage drug trial. 

The pivotal trial was for drug GTX-024, which prevents muscle mass from wasting away in lung cancer patients. The drug had nice market potential as a complementary therapy, and the FDA was interested enough to give it a fast-track designation, speeding up its approval process if its phase 3 trials went well.

In this video, health-care analyst David Williamson drills down on today's terrible news for GTx investors. Watch and find out why there was so much optimism around this drug and if, after the collapse, GTx makes for a bad-news buy.

Rising health-care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2601510, ~/Articles/ArticleHandler.aspx, 10/21/2014 8:18:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement